Genome editing products: FDA recommends at least 15 years of follow-up after clinical trials
By Zachary Brennan,
Endpoints News
| 03. 15. 2022
As Intellia recently unveiled its latest promising data around one in a series of potentially game-changing gene therapies, the FDA on Tuesday sought to further encourage the field with new draft guidance on what should be submitted in a clinical trial application and what potentially concerning safety issues to track for these genome editing products.
The agency is upfront about the risks of genome editing, as Allogene was hit with a clinical hold and preclinical studies suggest potential risks. The draft guidance points to several specific risks associated with genome editing, including off-target editing, unintended consequences of on- and off-target editing, and the unknown long-term effects of on- and off-target editing.
As such concerns linger, sponsors may be on the hook for a long and expensive follow-up to any clinical work. As part of efforts to further ensure the safety of such developing products, the guidance recommends at least 15 years of long-term follow-up after product administration, which is in line with past guidance on gene editing.
The agency also calls for adequate monitoring of any off-target editing and adequate...
Related Articles
By Marianne Lamers, NEMO Kennislink [cites CGS' Katie Hasson] | 09.23.2025
Een rijtje gespreide vulva’s gaapt de bezoeker aan. Zó ziet een bevalling eruit, en zó een baarmoeder met foetus. Een zwangerschap, maar dan zonder zwangere vrouw, gestript van zorgen, gêne en pijn. De zwangerschapsmodellen en oefenbekkens, te zien in de...
By Auriane Polge, Science & Vie [cites CGS' Katie Hasson] | 09.19.2025
L’idée de pouvoir choisir certaines caractéristiques de son futur enfant a longtemps relevé de la science-fiction ou du débat éthique. Aujourd’hui, les technologies de séquençage et les algorithmes d’analyse génétique repoussent les limites de ce qui semblait encore impossible. Au croisement...
By Charmayne Allison, ABC News | 09.21.2025
It has been seven years since Chinese biophysicist He Jiankui made an announcement that shocked the world's scientists.
He had made the world's first gene-edited babies.
Through rewriting DNA in twin girls' embryos, the man who would later be dubbed...
By Natalie Ram, Anya E. R. Prince, Jessica L. Roberts, Dov Fox, and Kayte Spector-Bagdady, Science | 09.11.2025
After declaring bankruptcy in March 2025, direct-to-consumer (DTC) genetic testing company 23andMe sold the data of more than 15 million people around the world to TTAM Research Institute, a nonprofit organization created by 23andMe’s founder and long-time CEO. 23andMe’s customers...